Novavax reports Q2 EPS 62c vs. 99c last year

Reports Q2 revenue $239.24M vs. $415.48M last year. “This quarter we continued to progress our growth strategy with key achievements including BLA approval for our COVID-19 vaccine, positive data from our COVID-19-Influenza-Combination and stand-alone influenza programs, advancement of our early-stage pipeline, and progression of our partnership strategy,” said John Jacobs, President and Chief Executive Officer, Novavax (NVAX). “We look forward to continuing to build on this foundation into the second half of the year.”